Table 2.
Summary of ETV efficacy either alone or in combination versus other nucleos(t)ide therapies in Chinese patients with drug-resistant CHBa
| ADV monotherapy | ADV add-on to LVD | ADV + ETV | ETV monotherapy | |||||
|---|---|---|---|---|---|---|---|---|
| (A) LVD-resistant CHB | ||||||||
| Ha et al39 | ||||||||
| HBV DNA undetectableb | 49 | 77 | 88 | NA | ||||
| ALT normalizationc | 72 | 80 | 88 | NA | ||||
| HBeAg lossb | 35 | 50 | 53 | NA | ||||
| HBeAg seroconversionb | 21 | 30 | 38 | NA | ||||
| Zhao et al38 | ||||||||
| ALT normalizationc | 75 | 84 | 100 | 93 | ||||
| LdT add-on to ADV | ETV monotherapy | |||||||
|
| ||||||||
| (B) ADV-resistant CHB | ||||||||
| Lu et al40 | ||||||||
| HBV DNA undetectabled | 73 | 57 | ||||||
| ALT normalizationd | 85 | 71 | ||||||
| HBeAg lossd | 33 | 11 | ||||||
| HBeAg seroconversiond | 20 | 0 | ||||||
| LVD add-on to ADV | ETV monotherapy | |||||||
|
| ||||||||
| Wang et al41 | ||||||||
| HBV DNA undetectablec | 97 | 68 | ||||||
| ALT normalizationc | 97 | 84 | ||||||
| HBeAg lossc | 47 | 8 | ||||||
| HBeAg seroconversionc | 37 | 4 | ||||||
Notes: All data are presented as percentage of patients, unless stated otherwise.
a
Direct comparisons cannot be made between studies due to differences in treatment periods and different experimental procedures between studies
b
24 months of treatment
c
12 months of treatment
d
48 weeks of treatment.
Abbreviations: ADV, adefovir; ALT, alanine transaminase; CHB, chronic hepatitis B; DNA, deoxyribonucleic acid; HBeAg, Hepatitis B e-antigen; HBV, hepatitis B virus; ETV, entecavir; LdT, tenofovir; LVD, lamivudine; NA, not applicable.